9 Meters Biopharma
NMTR
NMTR was delisted on the 25th of July, 2023.
39 hedge funds and large institutions have $4.45M invested in 9 Meters Biopharma in 2023 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 11 reducing their positions, and 7 closing their positions.
3,339% more call options, than puts
Call options by funds: $1.69M | Put options by funds: $49K
48% more capital invested
Capital invested by funds: $3M → $4.45M (+$1.45M)
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
5% less funds holding
Funds holding: 41 → 39 (-2)
64% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$2.08M |
| 2 |
CIBC Asset Management
Toronto,
Ontario, Canada
|
+$61.7K |
| 3 |
RCM
Requisite Capital Management
Dallas,
Texas
|
+$28.3K |
| 4 |
Cerity Partners
New York
|
+$20.2K |
| 5 |
Mercer Global Advisors
Denver,
Colorado
|
+$19.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$138K |
| 2 |
Renaissance Technologies
New York
|
-$111K |
| 3 |
Two Sigma Investments
New York
|
-$60K |
| 4 |
RWP
RWA Wealth Partners
Newton,
Massachusetts
|
-$48.9K |
| 5 |
Millennium Management
New York
|
-$46.7K |
NMTR Hedge Fund Activity: Q1 2023 in Review
39 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in 9 Meters Biopharma (NMTR) for Q1 2023, worth a combined $4.45M — up 48% from $3M a quarter earlier.
Fund positioning in NMTR was balanced in Q1 2023: 7 funds opened new positions, 7 closed out, 4 added to existing stakes and 11 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $2.08M. The largest seller was GSA Capital Partners, exiting entirely with an estimated $138K sold.
- 39 institutional investors held 9 Meters Biopharma (NMTR) as of Q1 2023, down from 41 in Q4 2022.
- Funds reported $4.45M of 9 Meters Biopharma stock for Q1 2023, up 48% quarter-over-quarter.
- 7 funds opened new 9 Meters Biopharma positions in Q1 2023 and 7 closed out, a net change of 0 holders.
- The largest 9 Meters Biopharma buyer in Q1 2023 was Sabby Management, an estimated $2.08M added.
- The largest 9 Meters Biopharma seller in Q1 2023 was GSA Capital Partners, an estimated $138K sold.
Based on aggregated 13F filings for Q1 2023.